Cover Image
市場調查報告書

藥物成癮的開發中產品分析

Drug Addiction - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 251560
出版日期 內容資訊 英文 95 Pages
訂單完成後即時交付
價格
Back to Top
藥物成癮的開發中產品分析 Drug Addiction - Pipeline Review, H2 2015
出版日期: 2015年10月28日 內容資訊: 英文 95 Pages
簡介

藥癮又稱為「耽溺藥物」,愈是成癮到破壞性的模式,要脫離該藥物就會愈加困難。藥物成癮患者主要的症狀及行動有頻繁使用藥物、不去履行職場·學校·家庭等應該採取的行為、失眠症、睡眠不規則化、異常懶惰感、厭食症/吃得過多症、用餐行為的變化、手掌體溫降低·發汗、手舞足蹈、眼睛充血·眼淚、瞳孔擴張/縮小、呼吸·人體·衣服發出異臭等。

本報告提供全球各國治療藥物成癮用的開發中產品開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

藥物成癮概要

治療藥的開發

  • 藥物成癮開發中產品:概要
  • 藥物成癮開發中產品:比較分析

各企業開發中的藥物成癮治療藥

大學/研究機關研究中的藥物成癮治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

藥物成癮治療藥:開發中的產品的一覽(各企業)

藥物成癮治療藥:研究中的產品的一覽(大學/研究機關別)

藥物成癮治療藥的開發企業

  • Gilead Sciences, Inc.
  • Aphios Corporation
  • Teva Pharmaceutical Industries Limited
  • Addex Therapeutics Ltd.
  • Biotie Therapies Corp.
  • Camurus AB
  • Curemark, LLC
  • Rottapharm SpA
  • Omeros Corporation
  • Immunovaccine, Inc.
  • 杏林製藥
  • D&A Pharma SAS
  • Embera NeuroTherapeutics, Inc.
  • Lightlake Therapeutics Inc.
  • SK Biopharmaceuticals Co., Ltd.
  • LondonPharma Ltd.

藥物成癮:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • nepicastat hydrochloride
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • ibudilast
  • buprenorphine hydrochloride
  • TV-1380
  • cannabidiol
  • (oxazepam + metyrapone)
  • SKL-N05
  • LT-22
  • ASB
  • methadone
  • GS-6673
  • dronabinol
  • ADX-88178
  • ADX-71441
  • OMS-527
  • Vaccine for Cocaine Addiction
  • Vaccine for Cocaine Addiction
  • MH-6 Vaccine
  • Vaccine for Drug Addiction
  • Ibogaine Analog
  • Small Molecules to Inhibit DAT for Cocaine Addiction and Cocaine Abuse
  • Small Molecules to Modulate 5HT2 for CNS and Metabolic Disorders
  • CM-1212
  • methoxycoronaridine
  • Small Molecules to Inhibit BRD for Cancer and Cocaine Dependence
  • CR-5542 Series
  • Small Molecules to Inhibit DAT and SERT for CNS Disorders
  • Small Molecules to Activate Delta Opioid Receptor for Immunology, CNS and Metabolic Disorders
  • Small Molecule to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction
  • Small Molecule to Activate Kappa Opioid Receptor for CNS
  • Small Molecule to Inhibit Kappa Opioid Receptor for CNS
  • Drug for Dependence

藥物成癮治療藥:開發中產品的最新趨勢

藥物成癮治療藥:暫停開發的產品

藥物成癮治療藥:中止開發的產品

藥物成癮相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全10件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7225IDB

Summary

Global Markets Direct's, 'Drug Addiction - Pipeline Review, H2 2015', provides an overview of the Drug Addiction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Drug Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Drug Addiction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Drug Addiction
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Drug Addiction and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Drug Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Drug Addiction pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Drug Addiction
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Drug Addiction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Drug Addiction Overview
  • Therapeutics Development
    • Pipeline Products for Drug Addiction - Overview
    • Pipeline Products for Drug Addiction - Comparative Analysis
  • Drug Addiction - Therapeutics under Development by Companies
  • Drug Addiction - Therapeutics under Investigation by Universities/Institutes
  • Drug Addiction - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Drug Addiction - Products under Development by Companies
  • Drug Addiction - Products under Investigation by Universities/Institutes
  • Drug Addiction - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Aphios Corporation
    • Astellas Pharma Inc.
    • Curemark, LLC
    • Embera NeuroTherapeutics, Inc.
    • Immunovaccine, Inc.
    • Kyorin Pharmaceutical Co., Ltd.
    • Lightlake Therapeutics Inc.
    • Omeros Corporation
    • Rottapharm SpA
    • Saniona AB
    • Teva Pharmaceutical Industries Limited
  • Drug Addiction - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (oxazepam + metyrapone) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • 18-MC - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ADX-71441 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ADX-88178 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASP-2905 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CM-1212 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CR-5542 Series - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dronabinol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug for Dependence - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EROA-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ibudilast - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JQ-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-22 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MC-100093 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • N-S2359 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OMS-527 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Drug Addiction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Activate Kappa Opioid Receptor for CNS - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate Delta Opioid Receptor for Immunology, CNS and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Block VMAT2 for Methamphetamine Addiction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit DAT and SERT for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Kappa Opioid Receptor for CNS - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Target 5HT2 for CNS and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide to Target Kappa Opioid Receptors for Drug Addiction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TV-1380 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Cocaine Addiction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Cocaine Addiction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Methamphetamine Addiction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Drug Addiction - Recent Pipeline Updates
  • Drug Addiction - Dormant Projects
  • Drug Addiction - Discontinued Products
  • Drug Addiction - Product Development Milestones
    • Featured News & Press Releases
      • Aug 13, 2015: Saniona Announces That FDA Has Approved The IND For NS2359 In Cocaine Addiction
      • Jun 16, 2015: MediciNova Announces New Article Published on MN-166 in Addiction Biology
      • May 28, 2015: Embera NeuroTherapeutics Initiates Phase 1 Clinical Trial to Test EMB-001 as a Novel Treatment for Addictions
      • Apr 10, 2015: HRA Pharma Closes Investment in Embera NeuroTherapeutics to Advance Development of Novel Therapies for Addiction
      • Sep 23, 2014: Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy
      • Aug 09, 2013: Curemark wins patent for CM-1212 to treat drug, alcohol addiction
      • Jun 18, 2013: MediciNova Announces Presentation Of Preliminary Results From Phase Ib Study Of MN-166 In Methamphetamine Addiction At 75th Annual Meeting Of CPDD
      • Feb 25, 2013: MediciNova's MN-166 Receives Fast Track Designation From FDA For Treatment Of Methamphetamine Dependence
      • Jan 18, 2013: Research team including Dr Gianluca Baio funded by the MRC
      • Jan 03, 2013: MediciNova Provides Development Update On MN-166
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Drug Addiction, H2 2015
  • Number of Products under Development for Drug Addiction - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Drug Addiction - Pipeline by Addex Therapeutics Ltd, H2 2015
  • Drug Addiction - Pipeline by Aphios Corporation, H2 2015
  • Drug Addiction - Pipeline by Astellas Pharma Inc., H2 2015
  • Drug Addiction - Pipeline by Curemark, LLC, H2 2015
  • Drug Addiction - Pipeline by Embera NeuroTherapeutics, Inc., H2 2015
  • Drug Addiction - Pipeline by Immunovaccine, Inc., H2 2015
  • Drug Addiction - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015
  • Drug Addiction - Pipeline by Lightlake Therapeutics Inc., H2 2015
  • Drug Addiction - Pipeline by Omeros Corporation, H2 2015
  • Drug Addiction - Pipeline by Rottapharm SpA, H2 2015
  • Drug Addiction - Pipeline by Saniona AB, H2 2015
  • Drug Addiction - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Drug Addiction Therapeutics - Recent Pipeline Updates, H2 2015
  • Drug Addiction - Dormant Projects, H2 2015
  • Drug Addiction - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Drug Addiction, H2 2015
  • Number of Products under Development for Drug Addiction - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top